HEV 239

HEV 239 is a recombinant protein-subunit vaccine developed to prevent infection by the hepatitis E virus (HEV). It contains virus-like particles derived from a specific fragment of the HEV genotype 1 ORF2 capsid protein (amino acids 368–606), produced using a recombinant Escherichia coli expression system. The vaccine is adjuvanted with aluminum hydroxide and administered intramuscularly in a three-dose schedule at months 0, 1, and 6. Clinical trials have demonstrated high immunogenicity and efficacy against symptomatic HEV infection—particularly for genotypes prevalent in Asia and Africa—with seroconversion rates near or at 100% after full vaccination. The primary indication is prevention of acute hepatitis E in adults aged ≥16 years; it has been licensed for use in China since 2011 and recommended by WHO for outbreak settings. Safety data show that adverse events are generally mild, mostly limited to local injection site reactions[1][2][3][4][5].

Brand names

Hecolin

Other names

hepatitis E vaccine (HEV 239)recombinant hepatitis E vaccineHecolin vaccine